Compare Neurocrine Biosciences Inc (NBIX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Western Union Co — how do they compare? Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B), while Western Union Co trades at $6.14 (market cap $1.97B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.3× Western Union Co's market cap, and Western Union Co pays a 14.85% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Western Union Co for 95 Days on average.
| NBIX | WU | |
|---|---|---|
Market Cap | $14.36B | $1.97B |
Volume | 1,237,180 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $185.50 | $10.28 |
52-Week Low | $123.10 | $5.90 |
Typical Hold Time | 23 Days | 95 Days |
Enterprise Value | $14.37B | $1.88B |
Dividend Yield | — | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Western Union (WU) trades at $6.145, up 0.57% on the day, with a mixed technical signal leaning bearish in moving averages but bullish overall. The company shows strong profitability with a 43.97% ROE and a net income margin of 9.79%, though revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent earnings have missed expectations in Q1 and Q2 2026, while the pending Intermex acquisition and a $200M cost-cutting plan aim to bolster future performance amid competitive pressures.
The stock presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, supported by a consensus price target of $6.86 offering ~12% upside. However, risks include earnings volatility, regulatory hurdles for the Intermex deal, and declining revenue trends. Analyst sentiment is cautious with only 12% buy ratings, suggesting a hold stance may be prudent until earnings stabilize and strategic initiatives show clearer results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
